The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction: Results From the Cooperative Cardiovascular Project
Abstract
Background and Purpose —Intracranial hemorrhage is a serious complication of thrombolytic therapy for acute myocardial infarction, especially among the elderly, but little information exists on estimating risk. Better estimation of risk in individual patients may allow for withholding or using alternate therapies among those at highest risk. Methods —To quantify the risk and identify predictors of intracranial hemorrhage associated with thrombolytic therapy, we performed a retrospective cohort study using data from medical charts. The study involved nearly all acute-care hospitals in the United States. All Medicare patients discharged with a principal diagnosis of acute myocardial infarction during a 9-month period in 1994 to 1995 were included. The main outcome measure was intracranial hemorrhage among those treated with thrombolytic therapy. Results —The rate of intracranial hemorrhage was 1.43% (455 of 31 732). In a logistic model, age ≥75 years, female, black race, prior stroke, blood pressure ≥160 mm Hg, tissue plasminogen activator (versus other thrombolytic agent), excessive anticoagulation (international normalized ratio ≥4 or prothrombin time ≥24), and below median weight (≤65 kg for women; ≤80 kg for men) were independent predictors. A risk stratification scale was developed on the basis of these factors: with none or 1 of the factors (n=6651), the rate of intracranial hemorrhage was 0.69%; with 2 factors (n=10 509), 1.02%; with 3 factors (n=9074), 1.63%; with 4 factors (n=4298), 2.49%; and with ≥5 factors (n=1071), 4.11% (Mantel-Haenszel; P <0.001). Conclusions —The rate of intracranial hemorrhage in older patients after treatment with thrombolytic therapy exceeds 1%. Readily available factors can identify elderly patients with acute myocardial infarction at high and low risk for intracranial hemorrhage associated with thrombolytic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
The Exclusion of the Elderly and Women From Clinical Trials in Acute Myocardial Infarction
Gurwitz, J. H. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110055029 · Cited by 532
Self-citationIncorporating Patients' Preferences into Medical Decisions
Kassirer, J. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302611 · Cited by 415
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Acute Myocardial Infarction in Women: A Scientific Statement From the American Heart Association
Mehta, L. S., Beckie, T. M., DeVon, H. A., Grines, C. L., Krumholz, H. M., Johnson, M. N., Lindley, K. J., Vaccarino, V., Wang, T. Y., Watson, K. E., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000351 · Cited by 1,244
Alexander, K. P., Newby, L. K., Cannon, C. P., Armstrong, P. W., Gibler, W. B., Rich, M. W., Van de Werf, F., White, H. D., Weaver, W. D., Naylor, M. D., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.182615 · Cited by 914
Self-citationBonnefoy, E., Lapostolle, F., Leizorovicz, A., Steg, G., McFadden, E. P., Dubien, P. Y., Cattan, S., Boullenger, E., Machecourt, J., Lacroute, J.-M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09963-4 · Cited by 605
Metadata
- Authors
- Brass, L. M., Lichtman, J. H., Wang, Y., Gurwitz, J. H., Radford, M. J., & Krumholz, H. M.
- Venue
- Stroke
- Published
- 2000-08
- Volume
- 31
- Issue
- 8
- Pages
- 1802-1811
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2139754057
- Cited by
- 170
- References
- 3
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.